Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity
Status:
Completed
Trial end date:
2002-12-01
Target enrollment:
Participant gender:
Summary
This study is in patients with at least moderate obesity (Body Mass Index [BMI] > 30 kg/m2 or
approximately 30 or more pounds overweight) and who also produce too much insulin (insulin
stores sugar as fat). Sandostatin LAR® Depot suppresses insulin, and is being developed to
help with weight loss in people who find it hard to lose weight on their own because they
produce too much insulin.
The main purpose of the study is to find the lowest dose of Sandostatin LAR® Depot that
safely helps overweight people lose weight. The study will also compare weight loss in obese
patients who receive one of three different dosages of Sandostatin LAR Depot or placebo.